Abstract
This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the “first and second line” drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.
Keywords: Synthesis, Cytotoxicity, Antibacterial, Antileishmanial, Biological Activities, Imidazolidine, Hexahydropyrimidine Derivatives, X-ray crystallography, Mycobacterium tuberculosis, heterocyclic compounds, E. coli
Medicinal Chemistry
Title:Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives
Volume: 9 Issue: 3
Author(s): Gustavo S. G. de Carvalho, Rafael M. P. Dias, Fernando R. Pavan, Clarice Q. F. Leite, Vania L. Silva, Claudio G. Diniz, Daniela T. S. de Paula, Elaine S. Coimbra, Pascal Retailleau and Adilson D. da Silva
Affiliation:
Keywords: Synthesis, Cytotoxicity, Antibacterial, Antileishmanial, Biological Activities, Imidazolidine, Hexahydropyrimidine Derivatives, X-ray crystallography, Mycobacterium tuberculosis, heterocyclic compounds, E. coli
Abstract: This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the “first and second line” drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.
Export Options
About this article
Cite this article as:
S. G. de Carvalho Gustavo, M. P. Dias Rafael, R. Pavan Fernando, Q. F. Leite Clarice, L. Silva Vania, G. Diniz Claudio, T. S. de Paula Daniela, S. Coimbra Elaine, Retailleau Pascal and D. da Silva Adilson, Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030005
DOI https://dx.doi.org/10.2174/1573406411309030005 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum
Current Topics in Medicinal Chemistry Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria
Recent Patents on Biotechnology Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-II
Current Topics in Medicinal Chemistry Metathesis Reactions. General Considerations
Current Topics in Medicinal Chemistry Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Editorial: Recent Advances in the Field of Kinases and Kinase Inhibitors
Current Pharmaceutical Design Prevalence of Latent Tuberculosis (LTB) Among Pregnant Women in a High Burden Setting in Sudan using Interferon Gamma (IFN- γ) Releasing Assay (IGRA)
Current Women`s Health Reviews Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Recent Developments in the Chemistry and Biology of G-Quadruplexes with Reference to the DNA Groove Binders
Current Pharmaceutical Design Design, Synthesis and Evaluation of Antimicrobial Activity of Novel Oxazine Derivatives using Betti’s Protocol
Letters in Drug Design & Discovery Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Molecular Docking Studies of the Antitumoral Activity and Characterization of New Chalcone
Current Topics in Medicinal Chemistry Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Anti Inflammatory and Anti Arthritic Activity of Different Milk Based Formulation of Curcumin in Rat Model
Current Drug Delivery Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Itraconazole vs Fluconazole as a Primary Prophylaxis for Fungal Infections in HIV-Infected Patients in Thailand
Current HIV Research Estimation of Affinity of HLA-A*0201 Restricted CTL Epitope Based on the SCORE Function
Protein & Peptide Letters